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Abstract: In the CellSearch® system, blood is immunomagnetically enriched for epithelial
cell adhesion molecule (EpCAM) expression and cells are stained with the nucleic acid dye
4′6-diamidino-2-phenylindole (DAPI), Cytokeratin-PE (CK), and CD45-APC. Only DAPI+/CK+
objects are presented to the operator to identify circulating tumor cells (CTC) and the identity of all
other cells and potential undetected CTC remains unrevealed. Here, we used the open source imaging
program Automatic CTC Classification, Enumeration and PhenoTyping (ACCEPT) to analyze all
DAPI+ nuclei in EpCAM-enriched blood samples obtained from 192 metastatic non-small cell lung
cancer (NSCLC) patients and 162 controls. Significantly larger numbers of nuclei were detected in
300 patient samples with an average and standard deviation of 73,570 ± 74,948, as compared to
359 control samples with an average and standard deviation of 4191 ± 4463 (p < 0.001). In patients,
only 18%± 21% and in controls 23%± 15% of the nuclei were identified as leukocytes or CTC. Adding
CD16-PerCP for granulocyte staining, the use of an LED as the light source for CD45-APC excitation
and plasma membrane staining obtained with wheat germ agglutinin significantly improved the
classification of EpCAM-enriched cells, resulting in the identification of 94% ± 5% of the cells.
However, especially in patients, the origin of the unidentified cells remains unknown. Further
studies are needed to determine if undetected EpCAM+/DAPI+/CK-/CD45- CTC is present among
these cells.
Keywords: circulating tumor cells; CellSearch®; EpCAM; leukocytes; ACCEPT; deep Learning;
classification; image analysis; non-small cell lung cancer
1. Introduction
Circulating tumor cells (CTC) are cells disseminated from the primary or metastatic tumor site
into the bloodstream. In several cancer types, including non-small and small cell lung, prostate, breast,
colon, bladder, gastric carcinoma, and melanoma, the presence of CTC in circulation is associated
with a poor survival rate of the patients [1–9]. With many blood cells circulating in our cardiovascular
system, CTC are rare events. A concentration of one CTC per mL of blood is already high, while the
concentration of white blood cells is around 5 × 106 cells and red blood cell concentrations reach up
to 5 × 109 cells per mL. When detecting CTC, it is therefore of utmost importance to locate all CTC
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present and have an extremely sensitive and specific assay to discriminate between the tumor cells
and blood cells. In the CellSearch® system, epithelial cell adhesion molecule (EpCAM) antibodies
coupled to ferrofluids are used for immunomagnetic enrichment of cells thereby removing the bulk of
leukocytes. After this, CTC are fluorescently labeled with: 4′6-diamidino-2-phenylindole (DAPI) to
stain the nucleus; phycoerythrin (PE) labeled antibodies recognizing cytokeratins (CK) 4–6, 8, 10, 13, 18,
and 19, which are present in the majority of cells derived from epithelial cancers, and allophycocyanin
(APC) labeled cluster of differentiation (CD) 45, which is present on the cell surface of leukocytes [10].
Images covering the surface of the CellTracks cartridge are acquired by the CellTracks Analyzer II, and
all events that are positive for both DAPI and CK are presented as thumbnail images to the operator,
who will decide which cells follow the criteria for CTC assignment. The identity and number of all
other nucleated cells are not provided, thereby obscuring any potential cells of interest. These cells
can now be explored using the open source image analysis program Automatic CTC Classification,
Enumeration and PhenoTyping (ACCEPT) (download on https://github.com/LeonieZ/ACCEPT).
The ACCEPT program is an open source toolbox designed to analyze and characterize all objects
present in the fluorescent images.
With this program, we analyzed 659 EpCAM-enriched blood samples, obtained from 162 healthy
donors or patients with benign disease and 192 metastatic non-small cell lung cancer (NSCLC) patients.
We pursued several methods to determine the extent and identity of all cell populations present,
in order to assess the number of cells that potentially are CTC.
We observed that the number of cells identified as leukocytes in the EpCAM-enriched fraction
was low and showed a large variance across the samples. We investigated several possible causes:
A possible correlation with sample or patient attributes, insufficiencies in the image analysis,
and insufficiencies in the staining of the leukocytes or its detection. To improve this last option,
we explored several avenues. We showed previously that addition of CD16, recognizing the FcγIIIa,
to the staining cocktail improved the identification of nuclei as granulocytes since they express CD45
at a lower level compared to lymphocytes and monocytes [11]. We now applied this antibody in
a large cohort of patient samples. We also explored an alternative LED excitation light source to
improve the excitation efficiency of the APC fluorochrome, as opposed to the mercury arc lamp which
is used as a light source in the CellTracks [12]. In addition, wheat germ agglutinin (wga), a lectin that
binds to sialic acid and N-acetylglucosamine residues, was explored because it is present on cellular
plasma membranes [13–18]. We examined the presence of a cell membrane by using wga conjugated
to AlexaFluor-488 and adding it to the CellSearch immunostaining cocktail.
In summary, we present a method to closely examine every cell present in the cartridge after
EpCAM enrichment. CTC subpopulations expressing low or no CK are currently not examined,
and their potential clinical utility remains unexploited. Here we describe several methods to discover
the extent of the anonymous cell population that could harbor these unidentified CTC.
2. Results
2.1. Enumeration of Nucleated Cells in the EpCAM-Enriched Cells
The image analysis program ACCEPT was used to enumerate the total number of nucleated cells
in the image files after EpCAM enrichment. Figure 1a–c shows an example of the ACCEPT analysis in
which the nucleated cells (blue dots) are identified among the other objects in the images (grey dots).
To identify nucleated cells in the cartridge images, showing the following criteria for DNA staining
were used: 1. Mean fluorescence intensity ≥50 (panel a); 2. standard deviation of the fluorescence
intensity ≥20; 3. Size <500 µm2 (panel a); and 4. Roundness <0.95, where 0 is a perfect circle (panel b).
To identify single cells, a perimeter to area (P2A) of <1.5 was used, for doublets a P2A between ≥1.5
and <2.5, for small clusters a P2A between ≥2.5 and <4, and for large clusters a P2A ≥4 (panel b). For
enumeration of nucleated cells, the doublets and clusters were counted as one. An example of the
single cells, double cells, and clusters that were identified in this manner are illustrated in Figure 1d–g.
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Figure 2 shows the nucleated cell count from 300 samples obtained from 192 NSCLC patients (mean
73,570 ± 74,948, median 47,192) and from 359 samples obtained from 162 healthy donors and patients
with benign disease (mean 4191 ± 4463, median 2729). The number of nucleated cells was significantly
larger in the patient samples as compared to the samples from healthy donors and patients with benign
disease (Mann-Whitney U test: p < 0.001).
For a complete analysis, we determined the association between the number of nucleated cells
and the sample type (“patients” or “controls”). For this analysis, 300 samples from metastatic NSCLC
patients and 359 samples from healthy volunteers and patients with benign disease were used.
First, several factors were investigated that could influence the nucleated cell count since these
factors were present in a limited set of patients or controls only. As the first factor, we evaluated the
influence of the assay itself by determining the nucleated cell count from 30 controls with benign
disease from which four blood tubes were obtained and processed simultaneously, see Figure S1.
It indicated that a coefficient of variation of less than 10.7% or more than 40.2% (mean of 25.6 ± 14.9%
(1 standard deviation)) of the nucleated cell count cannot be attributed to assay variation with a
97% certainty. This was only the case for six (20%) controls. The influence of the assay itself was
therefore excluded from further analysis. Second, undergoing treatment as a contributing factor
was considered. In 64 NSCLC patients, we observed that 95% of the patients showed an increase or
decrease in nucleated events of more than 10% during treatment, compared to the nucleated events at
the start of treatment, see Figure S1. We considered this a significant change and therefore this factor
was included in further analysis. The third factor investigated was gender. No influence of the gender
(133 male patients, 127 female patients, and 40 patients of unknown gender) on the nucleated cell
count was observed with the Mann-Whitney U test (p = 0.237), and the factor was therefore excluded
from further analysis.
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Figure 1. ACCEPT identification of nucleated cells. The three scatter plots in panels (a–c) were used 
to define nucleated cells (depicted in blue) by ACCEPT. In total, 104,504 events were detected and 
107,431 of them were classified as nucleated cells, whereas the other events are depicted as grey dots. 
The division into single cells, doublets, small, and large clusters was based on DNA perimeter to area 
ratio, as illustrated in panel (b). In the scatter plot in panel (c), the mean fluorescence intensity of 
Cytokeratin (CK)-phycoerythrin (PE) (CK mean intensity) is plotted against the mean fluorescence 
intensity of CD45-allophycocyanin (APC) (CD45 mean intensity). In panels (d–g) typical examples of 
the segmentation (red line) around the nucleus of a single cell are illustrated in panel (d); of a doublet 
in panel (e); a small cluster in panel (f); and a large cluster in panel (g). The white scale bar represents 
10 pixels, which corresponds to a size of 6.4 µm. 
Figure 1. ACCEPT identification of nucleated cells. The three scatter plots in panels (a–c) were used
to define nucleated cells (depicted in blue) by ACCEPT. In total, 104,504 events were detected and
107,431 of them were classified as nucleated cells, whereas the other events are depicted as grey dots.
The division into single cells, doublets, small, and large clusters was based on DNA perimeter to area
ratio, as illustrated in panel (b). In the scatter plot in panel (c), the mean fluorescence intensity of
Cytokeratin (CK)-phycoerythrin (PE) (CK mean intensity) is plotted against the mean fluorescence
intensity of CD45-allophycocyanin (APC) (CD45 mean intensity). In panels (d–g) typical examples of
the segme tation (red line) a ound the nucleus of a single cell are illustrated in p nel (d); of a doublet
in panel (e); a small luster i panel (f); and a large cluster in panel (g). The white scale bar represents
10 pixels, which corresponds to a size of 6.4 µm.
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Figure 2. Frequency distribution of the cell populations detected in CellSearch® and with the addition
of the CD16 classification after epithelial cell adhesion molecule (EpCAM) immunomagnetic enrichment
of 300 blood samples from 192 non-small cell lung c ncer (NSCLC) patients (filled circle) and 127 blood
samples from 20 healthy volunteers (open diamond). Healthy volu teer samples spiked with cell line
cells (n = 88) are indicat d with an op n squ r . Cell populations: All nucleated cells (grey), circulating
tumor cells (CTC) (gree ), CD45+ leukocytes (brown), CD45+/CD16- leukocytes (red), CD45-/CD16+
leukocytes (yellow), C 45+ CD16+ leukocytes (orange , and unidentified cells (blue). The differences
in cell count between the NSCLC patients and healthy volunteers in the same cell classific tion is
significant for all subclasses (p < 0.001). Samples from healthy volunteers were not spiked (diamond
symbol, n = 39; median 0 CTC) or spiked (square sy bol) with cancer cell lines PC3 (n = 47; median 63
CTC; 1.0 × 104 EpCAM antigens) and NCI-H460 (n = 41; median 1 CTC; 1.4 × 102 EpCAM antigens).
In the crude multiple regression analysis for all 300 NSCLC patients and 359 controls, the relation
between sample types “patient” and “control” was established. The result of this multiple regression
analysis is presented in Table 1. This was followed by an analysis to correct for patient age (younger vs.
older than 55 years). As a third analysis, we corrected for the patient variables: CTC count (continuous
variable), treatment (during treatment vs. before or no treatment) and sample age at the time of
processing with CellSearch (1 day vs. 2–4 days).
Table 1. Multiple regression analysis for association between sample type and nucleated events
corrected for several patient variables.
Analysis Type Regression Coefficient 95% Confidence Interval p-Value
Crude analysis 17.0 14.1–20.6 <0.001
Corrected analysis for ge 19.2 15.3–24.2 <0.001
Corrected analysis for age,
and patient variables (sample
age, CTC count and treatment)
12.4 9.4–16.4 <0.001
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Each variable was analyzed for its confounding effect on the number of nucleated events.
This showed that age of the patient, undergoing treatment, and CTC count had little confounding
effect (below 5%). The sample age showed a confounding effect of 11.7%.
2.2. Improved Image Analysis
The number of nucleated events present in some cartridges can be enormous (over 100,000 for
27% of the patients), covering the whole detection surface, while some cartridges barely hold any cells
(less than 5000 for 6% of the patients). The high number of cells creates a large area of packed cells,
which makes it difficult to define borders for each cell, either manually or by image analysis algorithms.
The segmentation quality of the ACCEPT toolbox was influenced by the number of cells present in
the sample, an illumination bias, and fragmented staining. This is illustrated in detail in Figure S2.
These problems motivated the use of a segmentation approach based on deep learning. As opposed to
the model-based approaches currently implemented in the ACCEPT toolbox, deep learning approaches
do not make any model assumptions about the signal (e.g., a nearly homogenous background and cell
intensity), but learn a model based on only the data used for the training.
2.3. Assignment of Nucleated Cells to a Cell Lineage
In the CellSearch system, CD45-APC is used to identify leukocytes and Cytokeratin-PE to identify
CTC among the nucleated cells. Nucleated cells expressing both CD45-APC and Cytokeratin-PE
are assigned as cells binding non-specifically to at least one of the antibodies. The number of CTC
identified by the classical CellSearch method in the 300 samples from 192 NSCLC patients ranged from
0–186 (mean 2; median 0) and represent only a very small portion of the nucleated cells identified in
the samples from these patients. To determine whether the identity of the majority of nucleated cells
could be assigned to the hematopoietic cell lineage by their expression of CD45, the thumbnails of the
nucleated cells were put into a trained deep learning network for segmentation and the segmented
images were fed back into the ACCEPT toolbox. Using the marker characterization processor tool,
the results could be visualized and analyzed. The improved segmentation allowed for a relatively
simple definition of cell subpopulations and in most cases a simple yes or no could be used to define
the presence or absence of a marker. The actual definitions of the different cell populations are listed in
Table 2. In this manner, nucleated cells were classified as CD45+, CD45- and CK- or CK+ in 300 samples
from 192 NSCLC patients and 127 samples from 20 healthy volunteers.
Table 2. The definition of cell populations used to classify cells in ACCEPT after deep learning
segmentation in 300 non-small cell lung cancer (NSCLC) patient samples and 127 samples from
healthy volunteers.
Cell Population
Mean Intensity Value Overlay Nucleus Size (µm2)







CTC CK+/CD45- >0 0 ≥50 0 >0 >0.4 ND ND >9
Leukocytes
CD45+/CD16- >0 >0 0 0 >0 ND >0 ND ND
CD45+/CD16+ >0 >0 0 >0 >0 ND >0 >0 ND
CD45-/CD16+ >0 0 0 >0 >0 ND ND >0 ND
Nucleus
Bare nucleus >0 0 0 0 0 ND ND ND ND
Unstained cell >0 0 0 0 >0 ND ND ND ND
1 Only for those samples in which CD16 or wga was added to the immunostaining cocktail. Abbreviations used:
DAPI: 4′6-diamidino-2-phenylindole; CD: cluster of differentiation; CK: cytokeratins; wga: wheat germ agglutinin.
As described in the method section, for this analysis, 10% of the nucleated cells found by the
ACCEPT toolbox, up to a maximum number of 5000 cells, were analyzed and the results were
extrapolated to the full number of nucleated events to arrive at the cell numbers. The number of
nucleated cells that could be identified as leukocytes in CellSearch was only 18% ± 21% (range 0–89%;
median 9%) in patients and 23% ± 15% (range 2–68%; median 19%) in healthy volunteers, see Figure 3.
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To be able to assign the cell lineage of origin of the nucleated cells on which no CD45- or CK-expression
could be detected, several approaches were pursued.
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(upper) and using CD16 expression (lower) for further classification of the cells.
2.4. Increasing Leukocyte Identification by Adding CD16 Immunostaining
Whereas CD45 is basically present on all human leukocytes, it is most strongly expressed on
lymphocytes and monocytes and expressed at a relatively low density in granulocytes. CD16 identifies
the Fc III receptor present on granulocytes and natural killers cells. We added anti-CD16 labeled
to PerCP to the CellSearch staining cocktail to improve the identification of granulocytes especially,
using 300 blood samples from 192 NSCLC patients and 127 blood samples from 20 healthy volunteers.
Thumbnail images of the nucleated cells identified by ACCEPT were fed into the trained deep learning
network as described above. Figure 4 shows typical thumb ail images of nucleated events identified
by ACCEPT using the presence of the different markers for classification. Classifi CTC with
expression of CD45 or CD16 can either be; (1) CTC nonspecifically binding to CD16 or CD45 antibodies;
or (2) leukocytes non-specifically binding to the cytokeratin antibodies. The distribution of these cell
populations in the patient and healthy volunteer samples is shown in Figure 3. From the 82% ± 21%
unidentified nucleated cells in 192 NSCLC patients, 62% ± 19% are identified as granulocytes through
CD16-expression. This decreases the number of unidentified cells to 20% ± 13% of the total nucleated
cells present in the cartridge. The percentage of CD45-expressing leukocytes that also express CD16 is
13%± 18 . These are most l kely natural killer cel that express CD45 in higher densities compared to
granulocytes. In 127 samples from 20 healthy volunteers, 77%± 15% of the cells are unidentified which
was decreased to 15% ± 9% when CD16 was used. The actual number of nucleated cells identified
Cancers 2018, 10, 377 7 of 16
by either CD45 or CD16 for patients and healthy volunteers is shown in Figure 2. The number of all
classifications of nucleated cells was significantly larger in patients compared to healthy volunteers
(p < 0.001). Figures 2 and 4 show there is still a large number of nucleated cells, especially in the
patients, that remain unidentified.
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Figure 4. ACCEPT gallery showing cells from all classifications using the presence or absence of several
markers. The scale bar is 10 pixels, representing 6.4 µm.
2.5. LED as a Light Source to Improve Excitation Efficiency of CD45-APC and CD16-PerCP
For five NSCLC patients and five healthy volunteers, cartridges were scanned first with the
CellTracks–equipped with a mercury arc lamp as a light source–followed by scanning on a microscope
equipped with an LED light source. The objectives and filter cubes were kept the same in both systems.
The mean percentage of CD45+/CD16- leukocytes found by the CellTracks was 8% ± 7% and this
increased to 16% ± 9% when a LED light source was used, as shown in Figure 5. More pronounced
was the increase for CD45+/CD16+ leukocytes, which increased from 1% ± 0% to 59% ± 25% with
the LED light source. Whereas CD16+/CD45- cells comprise a large population of the cells when a
mercury rc lamp is used, these cells also appear to be CD45+ en the LED light source was used f r
the analysis; CD16+/CD45- leukocytes decreased from 58 ± 17% to 19% ± 15%. In total, the number
of unidentified cells was reduced from 33% ± 14% to 6% ± 5% when an LED light source was used
instead of a mercury arc lamp.
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Figure 5. Improved identification of cells by comparison of cell population distributions analyzed with
the mercury arc light source in CellSearch (left), followed by analysis with a LED light source on a
separate microscope (right).
2.6. Identification of Unstained Nuclei by Adding Wheat Germ Agglutinin Immunostaining
In ten whole blood samples from five NSCLC patients and five healthy volunteers, the lectin
wga conjugated to Alexa-Fluor488 was added to the CellSearch staining cocktail for the identification
of cellular plasma membranes. In Figure S3, an ACCEPT gallery shows the staining of wga present
on all cell classifications. The absence of wga on a nucleus, classifies this event as a “bare nucleus”.
The presence of wga on already identified cells was 44% ± 23% for CD16+ granulocytes, 41% ± 20%
for CD45+ leukocytes and 88% ± 15% for CD45+/CD16+ leukocytes, see Figure 6. One healthy
volunteer sample was spiked with the cancer cell line MCF-7, and 100% of those spiked cells were
stained with wga. In contrast, 52% ± 23% of the unidentified cell population was stained with wga,
suggesting these are intact cells, whereas the remaining 48%± 23% of these nuclei appear to be without
a cell membrane. This suggests that these are simply bare nuclei, which cannot be identified through
immunofluorescence staining.
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Figure 6. Distribution of cell populations in samples with wheat germ agglutinin (wga)-AlexaFluor488
staining (n = 10). The stacked bar represents the five cell populations present in these cartridges. One
healthy volunteer sample was spiked with MCF-7 cancer cells, which are represented in the “CTC”
category (6%). Of each population, the percentage of cells that stained positive for wga is displayed on
the right side of the image, whereas the population remaining unstained with wga is visualized in rey.
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3. Discussion
In this study, we investigated the cell populations present in 659 cartridges after immunomagnetic
EpCAM enrichment by the CellSearch system, gathered from 162 healthy volunteers and 192 NSCLC
patients. Stored fluorescent microscope images of the surface of the cartridges were analyzed by
image analysis for the presence of different cell populations. The identity and number of cells present
in the EpCAM-enriched cell suspension is not known, since the software only detects and presents
DAPI+/CK+ events for review that are co-located. Any potential tumor cells or other interesting
events remain obscured. We therefore explored the identity of all events present in the cartridge after
EpCAM enrichment.
Images from the CellTracks microscope were analyzed with advanced imaging techniques. Most of
the image analysis tools that were used are already assembled in the open source imaging program
ACCEPT, including a tool to compare operator variability in scoring CTC [19,20]. In this image
data set we had to deal with samples of low image quality, unequal distribution of the illumination,
and extremely crowded images containing many clustered events, see Figure S2. A deep learning based
approach appeared to be a good solution since it could easily be adapted to a certain type of signal to
segment by feeding it with enough training data. The deep learning based segmentation algorithm was
programmed in Python® using the Keras [21] framework and is not yet linked to the ACCEPT toolbox,
which is developed in MATLAB®. To be able to use the deep learning based segmentation, we exported
thumbnails identified by ACCEPT and used them as input for the deep learning segmentation network.
After segmentation of the thumbnails by the network, the segmentation results, together with the
original thumbnails, were fed back into the ACCEPT toolbox for further analysis. For samples with
thousands of nucleated events (up to 300,000 with five fluorescent channels each), this became quite
a computationally intensive task. Therefore, for the current analysis we restricted that part of our
analysis to only 10% of the nucleated events which were randomly selected. Experience obtained with
the deep learning based classification algorithm we developed showed very promising results and the
new segmentation method also showed that it is often superior to the more traditional segmentation
approach currently used in ACCEPT [22]. Thus, in the future, we would like to incorporate a semantic
deep learning segmentation into the ACCEPT toolbox to automatically detect and classify CTC, tumor
derived extra cellular vesicles, leukocytes, and other cell populations for which reagents are added.
In total, 300 samples obtained from 192 metastatic lung cancer patients, 232 samples obtained
from 142 patients with benign tumors, and 127 samples obtained from 20 healthy volunteers were
investigated for the presence of nucleated events. The number of nucleated events was significantly
higher in cancer patients as compared to the healthy donors and patients with benign disease,
see Figure 2 and Figure S1, and further studies are needed to explore the potential clinical utility of this
finding. CTC were detected by traditional CellSearch scoring in a small portion of the patient samples
and in these samples the CTC number ranged from 1 to 186 cells. This low number of cells could not
account for the large differences in the detected nucleated events.
Knowledge of the composition of these nucleated cells is needed to be able to hypothesize about
this difference. Most likely, these nucleated events originate from hematopoietic cells that are captured
along with the EpCAM enrichment in CellSearch. However, the fraction of nucleated cells on which the
leukocyte marker CD45 was detected was remarkably low both in healthy volunteers and metastatic
cancer patients, as shown in Figure 3. Since the excitation of CD45-APC with a mercury arc lamp
used in the CellTracks system is not optimal, we first looked into a way to increase the detection of
granulocytes especially, which express the CD45 antigen in relatively low antigen density compared
to leukocytes.
We evaluated this by adding anti-CD16-PerCP antibody to the immunostaining in the CellSearch
system. All 300 samples from metastatic lung cancer patients and 127 samples from healthy volunteers
were processed with this extra marker. The leukocytes and granulocytes that were identified indeed
increased, as shown in Figure 3. However, a considerable number of nucleated cells remained
unidentified. Next, we looked into the role of ferrofluids, which are used at a concentration of 40 µg/mL
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in CellSearch and are present on the imaging surface of the cartridge [23,24]. The ferrofluids reduce the
intensity of the fluorescence; an effect which is most obvious in the blue region (400–460 nm). Therefore,
we looked into an improvement of the excitation of the fluorophores. For this, a microscope equipped
with an LED light source to improve the APC fluorophore excitation was used [12]. This resulted
in a clear decrease of unidentified nucleated cells, see Figure 5. Also, to determine whether these
remaining nuclei were enclosed by a cellular plasma membrane, we added wheat germ agglutinin to
the CellSearch cocktail [13,14]. This showed that part of the unidentified nucleated cells did not stain
with wga, suggesting they are “bare”-like nuclei, see Figure 6.
Whether or not these bare nuclei were actually present in the blood, or if they represent
cells that have been damaged through the immunomagnetic selection or staining process, remains
an outstanding question. However, a large fraction of leukocytes identified with the current
immunostaining are not also stained with wga. This could suggest that the wga-staining assay
is not sufficiently sensitive to stain all membranes or that the imaging method is not sufficiently
sensitive to detect dim wga fluorescence. A high concentration of wga added to the CellSearch
cocktail caused the aggregation of blood cells, and therefore a lower concentration was chosen for
this assay. It might, however, be possible that a higher concentration of wga is necessary to locate
all membranes present in the blood sample. Also, all samples were analyzed on the CellTracks,
but improved identification will be observed when the LED light source is used. Another option
is that the leukocyte membranes are damaged to a point that the agglutinin can no longer bind to
the residues on the membrane. This may be caused during the 15 min permeabilization process to
open the membranes. The CellSearch permeabilization agent is saponin, a detergent which interacts
with membrane cholesterols by selectively removing them to form pores, which enables antibodies to
enter [25]. It is notable, that the fraction of the spiked MCF-7 cancer cells that were stained with wga
was 100%. Compared to cancer cell line cells, the leukocytes are possibly more fragile and susceptible
to damage caused during permeabilization.
The wga+/DNA+/CD45-/CD16-/CK- cells are potentially CTC that are not expressing CK for
CellSearch detection. However, our observation that a similar population was detected in the blood
of healthy volunteers makes this explanation less likely. Confirmation of whether or not CTC are
among the unidentified nucleated cells will likely have to come from DNA or RNA assays. Removing
the cells from the cartridge might allow them to be selected based on their absence of fluorescence
markers and subsequently sorted with fluorescence-activated cell sorting (FACS). Quantitative PCR
after DNA isolation and amplification could reveal the presence of mutations, indicating one of the
cells is, in fact, a tumor cell. Digital-droplet PCR has a higher sensitivity and could be applied on the
entire cell suspension from a cartridge, although the multiplex analysis of mutations is less feasible in
this assay. With these approaches, the number of tumor cells will have to be compared to the number
of CTC scored on the CellTracks (if present at all) to determine if more or an equal number of tumor
cells are present in the cell suspension. Also, analysis of mRNA after FACS isolation might be feasible
for the unidentified cells with a cellular membrane present. Quantification of a selection of proteins can
indicate if the cells are of hematopoietic of epithelial lineage. However, the permeabilization of cells in
the CellSearch might complicate this approach. Therefore, the CellSearch Epithelial Cell Profile Kit
should be used. This kit is designed for RNA analysis and enriches EpCAM+ cells without subsequent
permeabilization and staining.
After taking several steps to determine the origin of unidentified cells, the possible identity for
the cells that remained unidentified thus far might be:
1. Hematopoietic cells not identified through damage incurred during the procedure or inaccessible
antigens through the ferrofluids [23,24];
2. Hematopoietic cells without sufficient expression of CD45 and CD16: This suggests they would
need additional CD markers for identification or an improved labeling method that amplifies
low signals, which might yield increased detection of very dim stained cells and separate the
fluorescent signal of densely packed cells [11,26–28]. Early myeloid cells have recently been
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observed to surround the tumor in high numbers, and as these cells do not yet express CD16,
this remains a possibility [29];
3. CTC with no or low expression of the CK antigens detected by the C11 and A53.B/A2 clones: Since
these clones only recognize a subset of the CK present in a cell, it might be beneficial to include
antibody clones that recognize all CK. Previously, we have shown that adding several CK clones
to the CellSearch antibody cocktail improved the detection of CTC positive patients by 11% [30].
Also, it might be possible that EpCAM+/CK- CTC are present, remaining undetected because of
the downregulation of epithelial markers through epithelial-to-mesenchymal transition [31–33].
In order to detect these cells, antibodies specific to this process could be added to the CellSearch
immunostaining [34–36];
4. Cells of other origin: Such as circulating stromal, endothelial, or stem cells [37]. Detection of
these cells would also require the addition of other antibodies to the assay.
Therefore, there is still much to be achieved toward the identification of the cells that remain
anonymous. It is most important to determine if all tumor cells have been located or if some are
still missed.
4. Materials and Methods
4.1. Cancer Patients, Patients with Benign Disease, and Healthy Volunteers
Peripheral blood samples were drawn by venipuncture into 10 mL CellSave Preservative Tubes
(Menarini Silicon Biosystems, Huntingdon Valley PA, USA) from healthy volunteers and metastatic
NSCLC patients. A total of 300 blood samples from 192 NSCLC patients were obtained after patients
with advanced NSCLC provided written informed consent. The medical ethical committee of the
University Medical Center Groningen and Board of Directors approved the protocol (project number
288.194/7 April 2014; Groningen, The Netherlands). Blood draw from patients occurred before
and/or during their treatment. A total of 127 blood samples from 20 healthy volunteers aged 20–55
were obtained from the donor services of the Experimental Centre for Technical Medicine at the
University of Twente, and all donors gave written informed consent before donating blood. All healthy
volunteer samples were processed 1 day after blood draw, whereas patient samples were processed
after 1–4 days. Digitally stored images from 232 samples from 142 patients with benign disease
processed with CellSearch from previous studies were included for ACCEPT analysis [10,38].
4.2. Cell Lines and Spiking
Whole blood samples from healthy volunteers were spiked with cancer cell lines PC3, NCI-H460,
and MCF-7. PC3 (1.0 × 104 EpCAM antigens) and NCI-H460 (1.4 × 102 EpCAM antigens) were used
for frequency detection of CTC with ACCEPT and MCF-7 (8.8 × 105 EpCAM antigens) was used for
testing wheat germ agglutinin (wga) staining of cancer cells. This cell line was chosen for its high
EpCAM expression to ensure sufficient capture of cancer cells in the cartridge for analysis. All cell lines
were obtained from ATCC (Manassas, VA, USA) and have not been authenticated in the past six months.
The cells were grown at 37 ◦C and 5% CO2 and cultured in RPMI-1640 (Sigma-Aldrich, St. Louis,
MO, USA). The culture media was supplemented with L-Glutamine (Sigma), 10% fetal bovine serum
(Gibco, Invitrogen, Carlsbad, CA, USA), and 1% penicillin-streptomycin (Gibco, Invitrogen, Carlsbad,
CA, USA).
4.3. Processing Blood with CellSearch
Aliquots of 7.5 mL of blood were processed with the CellSearch® system (Menarini Silicon
Biosystems, Castel Maggiore (BO), Italy) for CTC detection. CellSearch analysis was performed
within 96 h after blood was drawn. Antibodies directed against the epithelial cell adhesion antigen
(EpCAM) coupled to ferrofluids were used to enrich CTC from the background of leukocytes. The
enriched cells were fluorescently labeled with the CellSearch CTC kit (Menarini Silicon Biosystems)
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using the nucleic acid dye 4′6-diaminodino-2-phenylindole (DAPI) for DNA staining, anti-cytokeratin
monoclonal antibodies (mAbs) C11 and A53.B/A2 labelled with phycoerythrin (PE), and anti-CD45
mAb (clone HI30) labeled with allophycocyanin (APC) for recognizing leukocytes. Peridinin Chlorofyll
A Protein (PerCP) labeled mAb anti-CD16 (clone 3G8, Biolegend, San Diego, CA, USA) directed against
granulocytes, and Alexa-Fluor488 conjugated to the lectin wga (Thermo Fisher Scientific, Waltham,
MA, USA) were added to the extra marker position in the CellSearch Epithelial Cell kit with an
end concentration of 2 µg/mL and 3 µg/mL, respectively. This extra marker channel was used for
the measurement of PerCP and DIOC on the CellTracks Analyzer II, which generates images of the
complete cartridge for all channels.
4.4. Image Acquisition
Fluorescent microscopy images were acquired using a modified CellTracks Analyzer II, which
included a 20× and 40× objective and in total six filter cubes next to the standard instruments. Besides
the acquisition of the standard channels DAPI, PE, DIOC, and APC, the images with PerCP staining
were acquired with a customized PerCP filter cube (excitation 435/40 nm; dichroic 510 nm; emission
676/29 nm (Semrock, Rochester, NY, USA)) using an integration time of 400 ms. When wga was used
in the immunostaining, the integration time of the DIOC filter was also 400 ms. To determine if another
light source detects weakly stained leukocytes better than the mercury arc lamp of the CellTracks,
ten cartridges were automatically scanned with an inverted Nikon Ti-E microscope with filter cube
and objective changer (Nikon, Tokyo, Japan). The light source of this microscope is the Lumencor
Sola SE II 365 LED. A 10× (0.45NA) objective (Nikon, Tokyo, Japan), a computer-controlled CCD
camera (C114400, Orca Flash 4.0LT, Hamamatsu Photonics, Hamamatsu, Japan), an ASI MS-2500 XY
stage and filters optimized for LED illumination were used for the acquisition of fluorescent images of
the cartridge. The following filters (all from Semrock) were used: DAPI with excitation 377/50 nm,
dichroic 409 nm, emission 409 nm/LP; fluorescein isothiocyanate (FITC) with excitation 482/18 nm,
dichroic 495 nm, emission 520/28 nm; PE with excitation 543/22 nm, dichroic 562 nm, emission
593/40 nm; APC with excitation 635/18 nm, dichroic 652 nm, emission 680/42 nm; and PerCP with
excitation 435/40 nm, dichroic 510 nm, emission 676/29 nm. The integration times were the same
as used in the CellTracks: For DAPI 30 ms, FITC 100 ms, PE 200 ms, APC 600 ms, and for PerCP
400 ms. The scanning and image acquisition was controlled by a software program written in Labview
(National Instruments, Austin, TX, USA).
4.5. Image Analysis with ACCEPT
In CellSearch, CTC are annotated when the objects are stained with DAPI and CK, but lack CD45
staining and are larger than 4 µm with morphological features consistent with those of a cell [10,38].
In the ACCEPT (Automated CTC Classification, Enumeration, and PhenoTyping) toolbox, every event
in the images is analyzed using an advanced multi-scale segmentation approach and several intensity
and shape measurements are extracted for every event found [19,39]. ACCEPT is developed in the
EU funded “CANCER-ID” and “CTC-Trap” programs, as an open source toolbox for CTC analysis
and can be downloaded from https://github.com/LeonieZ/ACCEPT. New tools and features for
ACCEPT are being developed and made available in the downloadable version at regular intervals.
For this study, the fluorescent images from all samples were uploaded, and all events present in
the images were detected. To enhance the detection of cells, especially in areas where the cells formed
large cell clusters, we added a background subtraction to the ACCEPT toolbox. Before images are
segmented, a Fourier filtering is applied, and large and very fine scales are filtered by multiplying
the filtered signal with two Gaussian kernels before the signal is back-transformed by an inverse
Fourier transformation. In this way, the background is removed, which enhances the detection in very
crowded areas, as well as areas with inhomogeneous illumination.
Fragmented fluorescent signals make a segmentation with an intensity-based segmentation
method difficult, which is now implemented in the downloadable version of the ACCEPT toolbox.
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In this study this was especially observed in the fluorescent images obtained from the CD16-PerCP
stained cells. Therefore, we decided to explore deep learning approaches to determine if this limitation
could be overcome. For this approach, all thumbnails containing nucleated cells in the cartridge were
found using ACCEPT, and a random selection of these thumbnails was used for further evaluation.
Per sample, we exported 10% of the observed cells, but minimally 1000 (if the total amount was
high enough) and maximally 5000 thumbnails. Moreover, we exported 759 thumbnails with five
fluorescent channels each where the segmentation method of ACCEPT gave satisfactory results.
We used these thumbnails (split into single channels) to train a deep learning network to segment
the cells. The implementation was done in Keras and we used the U-net architecture with skip
connections [21,40]. The set of 3796 thumbnail images was split into a training set of 3037 images (80%)
and a validation set of 759 images (20%). The images were preprocessed in the following way: Each
thumbnail exported from the ACCEPT toolbox was transformed into a thumbnail of 80 × 80 pixels
by adding a padding at all four sides with the median intensity of the pixels at the image boundary.
Moreover, all images scanned with CellTracks were cast from double to uint8 arrays by first dividing
by 4095 (the maximum value in Celltracks) and then multiplying by 255 and converting the results to
uint8. Images scanned with the inverted Nikon Ti-E microscope were recorded as uint16, thus having
a theoretical maximum value of 65,535. However, during our analysis, we noticed that this range was
not used and that the range of intensity values used strongly differs between the fluorescent channels.
Therefore, we calculated for each fluorescent channel the intensity value that was higher than 99.9% of
the measured intensities over all images in all samples. The images were then divided by the resulting
intensity per channel, multiplied by 255 and cast to uint8. By taking the value that is above 99.9%
instead of the maximum, we accounted for individual saturated pixels where the incident light caused
the camera sensor to respond with the highest possible value. To train the deep learning network,
we used a batch size of 16 and the network was trained for ten epochs. The resulting convolutional
network was then used to segment the exported thumbnails for each sample. The original thumbnails
together with the segmentation derived by deep learning were fed back into the ACCEPT algorithm
by using the marker characterization processor for further analysis and visualization of results.
4.6. Statistical Analysis
Statistical analysis was performed using SPSS (version 24, SPPS Inc., Chicago, IL, USA). A p-value
below 0.05 was considered significant. The non-parametric Mann-Whitney U test with significance
level α = 0.05 was used to determine if there was a difference in nucleated cell numbers between
cohorts of patients and controls. The total nucleated cell amounts were log-transformed for normality.
With multiple regression analysis, we determined the association of several variables with the
total nucleated cell count, such as age, treatment, CTC score, and sample age before processing.
The confounding effect of each variable was also determined.
5. Conclusions
Advanced image analysis was used to identify the cell populations present after immunomagnetic
EpCAM enrichment by the CellSearch system from 659 cartridges from NSCLC patients. A significantly
larger number of nucleated cells were found, from which the origin could not be identified, compared to
samples from healthy volunteers and patients with benign disease. A large portion of the unidentified
nucleated cells could be identified by: Adding CD16 to improve the identification of granulocytes;
the use of an LED light source to improve fluorescence detection and; the addition of wga to
discriminate between bare nuclei and cells. However, there is still much to gain in the identification of
the cells that still remain anonymous. These observations must also be confirmed in patients with other
cancers. The question remains: What are these cells? Going forward, it is most important to determine
if all tumor cells have been located or if some are still missed and reside in this unidentified cell
population. This unidentified CTC subpopulation could be of interesting clinical value and remains
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thus far unexploited. Therefore, further studies are needed to determine if EpCAM+/CK- CTC are
present among the nucleated cells of which the origin is not known.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/10/10/377/
s1, Figure S1: Nucleated cell count in controls with benign disease and NSCLC patients, Figure S2: Illustration of
the issues that influence the segmentation quality of the ACCEPT toolbox, Figure S3: ACCEPT gallery of cells
stained with the membrane lectin wheat germ agglutinin (wga).
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